Recently, Sinopeg has achieved another significant milestone in the field of drug delivery carriers. Methoxy polyethylene glycol polylactide (mPEG-PLA-(2+2)K) has successfully passed the review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) and has officially completed pharmaceutical excipient registration and filing.

I. About mPEG-PLA

mPEG-PLA is a novel amphiphilic block copolymer composed of hydrophilic polyethylene glycol (PEG) and biodegradable polylactide (PLA).

Key Characteristics:mPEG-PLA combines the excellent hydrophilicity of PEG with the biodegradability and thermal stability of PLA. In vivo, it naturally degrades into non-toxic substances (polyethylene glycol and lactic acid), offering high biocompatibility and safety.

Application Value:As a drug delivery carrier, mPEG-PLA is an ideal choice for preparing long-acting sustained-release microspheres, nanomicelles, liposomes, and biodegradable medical devices (such as sutures and tissue engineering scaffolds).

II. Why is CDE Filing So Important?

According to the NMPA regulations on associated review and approval of active pharmaceutical ingredients, excipients, and packaging materials, pharmaceutical excipients must be registered on the CDE platform and undergo associated review with drug product registration applications.

Compliance Foundation:Completing the filing signifies that the quality standards and production systems for Sinopeg's mPEG-PLA meet the stringent requirements for pharmaceutical excipients in China.

Customer Enablement:This filing will greatly streamline the associated review process for downstream pharmaceutical customers when applying for innovative formulations (especially long-acting injectable formulations). It provides solid compliance documentation support to shorten R&D cycles and accelerate product launch.

III. Synergistic Multi-Product Empowerment

Beyond mPEG-PLA, Sinopeg has also completed compliance filings for several other block copolymer pharmaceutical excipients, including:

• mPEG-P(Glu)40 (Methoxy polyethylene glycol polyglutamate sodium):Completed CDE filing (Reg. No. F20210000395) and FDA DMF filing (DMF 036663).

• mPEG-P(LYS)40 (Methoxy polyethylene glycol polylysine hydrochloride):Completed CDE filing (Reg. No. F20240000691) and FDA DMF filing (DMF 041172).

The Sino-US dual-filing strategy for the above two products provides efficient compliance documentation support for customers in both domestic and international drug product applications.

IV. Why Choose Sinopeg?

As a pioneer in the drug delivery systems field, Sinopeg is committed to providing global customers with high-quality excipient products and CDMO services.

• Extensive Compliance Experience:To date, the company holds 16 CDE-filed products and 22 Drug Master Files (DMFs) that meet FDA requirements.

• Rigorous Quality System:The company is certified to ISO 9001, ISO 13485, ISO 14001, and ISO 45001. Its laboratories and production workshops are designed and constructed in strict accordance with the US FDA's cGMP standards.

• Strong R&D Capabilities:Holding over 40 invention patents, Sinopeg has accumulated deep technical expertise in liposomes, LNP delivery, long-acting formulations, and other areas.

With the successful filing of mPEG-PLA, Sinopeg's product line layout has become more comprehensive. We will continue to uphold the spirit of "Innovation, Leadership, and Development," supporting domestic and international pharmaceutical companies in overcoming drug delivery challenges and jointly promoting the high-quality development of China's biomedical industry!